At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 20, 2026 at 07:30 ET
Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, consolidating full global rights to the CD38-directed antibody. The deal includes a $100 million upfront payment and up to $750 million in potential milestone payments, plus tiered royalties on future sales in China.
- Biogen acquires exclusive Greater China rights to felzartamab from TJ Biopharma
- Total potential deal value: up to $850 million ($100M upfront, $750M in milestones)
- Biogen now holds full worldwide rights to felzartamab, a potential pipeline-in-a-product for immune-mediated diseases
- Felzartamab is in global Phase 3 trials for IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and kidney transplant rejection
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access